See how researchers are working hard to find new ways to battle and defeat cancer – and how you can join the fight!
Spread the word! Research plays a crucial role in the fight against cancer!
NCI: Why I Do Cancer Research
In this video from the National Cancer Institute (NCI) Dr. Ted Timble, Director of NCI’s Center for Global Health, shares why he has committed his career to cancer research. It is estimated that around the world, there will be 14 million people will be diagnosed with cancer this year. More than 8 million people will die. Cancer research helps to reduce these numbers by improving treatment, symptom management, and survivorship.
TAILORx Trial Finds Most Women With Early Breast Cancer Do Not Benefit From Chemotherapy
TAILORx is a phase 3 clinical trial that began in 2006. The trial found that 70% of women with the most common type of breast cancer (HR-positive, HER2-negative, node-negative breast cancer), when it is caught early, may be able to avoid chemotherapy.
Women age 75 or younger who find this type of cancer early (early stage) can get a 21-gene expression test (a type of genetic or DNA test). Then they can discuss the results with their doctor for guidance on choosing the right treatment for them. If the test results say she has low or immediate risk of the cancer coming back, she may be able to get hormone treatment only, without getting chemotherapy. The TAILORx study found that chemotherapy did not give any extra benefit for most of these women.
“ TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy” originally posted by the National Cancer Institute.
New Treatment Approach for Some Patients with Early-Stage Pancreatic Cancer
Two new clinical trials show a good outlook for early-stage pancreatic cancer if treated with surgery. In one trial, patients on a multi-drug regimen chemotherapy lived longer after surgery than those on single-dose chemotherapy. In the other trial, patients given chemotherapy and radiation before surgery lived longer than patients who only received chemotherapy after surgery. These important trials will add new treatment options for patients with early-stage pancreatic cancer.
“Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer was originally published by the National Cancer Institute.” Click link to learn more.
Drug Prevents Chemo-Related Hearing Loss in Some Children
One side effect of chemotherapy for some children with cancer is hearing loss. According to a new study, the drug sodium thiosulfate can protect the hearing of children with cancer undergoing treatment with the chemotherapy drug cisplatin.
Today, more than 80% of children diagnosed with cancer are alive at least 5 years after diagnosis. Many of these children are considered cancer free. Researchers are now aiming to reduce the long-term side effects that children experience with many cancer treatments. These can include heart or lung problems, cognitive difficulties, infertility, and hearing loss.
The participants in the trial were randomly assigned to receive sodium thiosulfate 6 hours after each cisplatin treatment or to receive only cisplatin. The children in the sodium thiosulfate group were half as likely to experience permanent hearing loss than children who received cisplatin alone, the researchers reported.
“Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children was originally published by the National Cancer Institute.”
Join Research Studies
You and your loved ones can speed up research advances by taking part in cancer-related research studies that interest you.
NCI: Steps to Find a Clinical Trial
Paying for Clinical Trials
A clinical trial is a scientific study to find out which treatments or devices are safe and if they work well. They help doctors learn about cancer and develop better treatments that can help you and other people in the future.
It is important to take part in clinical trials. Trial participation can lead to important benefits for patients, such as improved disease outcomes and better health. In this video, the National Cancer Institute, shows the different costs in a clinical trial and who has to pay for which costs.
“Paying for Clinical Trials Video” originally posted by the National Cancer Institute
“Clinical Trials” information originally posted by the Centers for Disease Control and Prevention
NIH All of Us Research Program
Join the All of Us Research Program to become a part of history. The All of Us Research Program is a historic effort to gather data over many years from a million or more people living in the United States. The goal is to move forward in research and improving health. This research program will serve as a national research resource to inform thousands of research studies, covering a wide variety of health conditions. For more information visit the All of Us website https://www.allofus.nih.gov/about.
NIH and Prostate Cancer Foundation Launch Large Study on Aggressive Prostate Cancer in African-American Men
African American men are more likely to get aggressive prostate cancer, which grows and spreads quickly, compared to other men. RESPOND is a new study that aims to understand why this is. The NIH and Prostate Cancer Foundation are funding the study, which will enroll 10,000 African American men with prostate cancer to look at the role of genes (DNA), social stress, and other risk factors.
African-American men have about a 15 percent chance of developing prostate cancer. While, white men have about a 10 percent chance of developing prostate cancer. African-American men are more likely to be diagnosed with aggressive disease. The risk of dying from prostate cancer is about 4 percent for African-American men and about 2 percent for white men. Researchers plan to learn more about why these disparities exist from this study.
Investigators in the study will examine possible associations between aggressive disease and exposures to neighborhood/environmental stressors such as discrimination, early-life adversity, and segregation. They will also study DNA and tumor samples to identify gene variants associated with aggressive prostate cancer. Once researchers have identified genetic changes associated with aggressive prostate cancer, they will investigate how the social environment interacts with those genetic changes.
To read more about this study please visit the link below.
“NAVIGATE is an opportunity for VA and NCI to partner at the national level to make clinical trials more accessible to veterans,” said James H. Doroshow, M.D., deputy director for Clinical and Translational Research, National Cancer Institute (NCI).
VA has a strong clinical research program. There are clinical trials in cancer and other diseases at close to 100 sites. VA facilities face challenges in starting and completing funded trials. It is difficult for partners to navigate the system. This program will address barriers to trial enrollment that veterans often experience. VA investigators will be able to identify important studies for veterans with cancer.
Click on the link below to read the full article from the National Cancer Institute.